All Articles

With a Wall Street veteran as CFO and a top cardiologist as advisor, Australian AI firm Echo IQ is executing a calculated assault on the U.S. healthcare market.

Imbria's ninerafaxstat gains FDA Orphan Drug status for nHCM, a rare heart condition. This strategic win pits its unique metabolic approach against rivals.

Millions of Americans with multiple illnesses face a maze of uncoordinated care. A new research partnership aims to prove a better model works—at home.

A major investment from New Mountain Capital positions RRC Companies to scale its critical engineering services for the rapidly expanding green energy sector.

Heparin, a trusted blood thinner, can trigger a fatal immune reaction. A small biotech's novel drug is now taking the global stage with a targeted solution.

Behind a standard executive announcement lies a strategic play. Genesis is bringing in a proven growth leader to navigate the competitive U.S. luxury market.

Veritone's upcoming AI showcase is a critical test. Can its impressive technological advancements overcome serious financial headwinds and prove its value?

Investment is returning to US construction, but a new analysis reveals a critical paradox: growth is now dictated by an aging power grid, labor shortages, and fragile supply chains.

As Whirlpool touts its 115th anniversary, a deeper look reveals a calculated strategy of American exceptionalism in a cutthroat global appliance market.

IHOP's new Dubai Chocolate Pancake isn't just a menu item; it's a case study in modern brand strategy, blending grassroots innovation with Gen Z's digital clout.

The autism community has spoken: wellbeing is essential. A new survey reveals a deep disconnect and a call for a paradigm shift away from mere skill-building.

Ottawa is investing over $17M to shield its health system from climate change. Is this new prescription enough to cure our national adaptation deficit?

After a 30-year hiatus, Hardee's is back in NASCAR. Its new Bubba Wallace meal reveals a sophisticated strategy blending nostalgia, celebrity, and culture.

With a new factory expansion backed by public funds, UbiQD isn't just growing; it's cementing New Mexico's role in the deep-tech race. What's the why behind this buy?

A novel drug for glioblastoma enters a revolutionary trial, but the real story is the mission-driven company behind it, rewriting the rules of drug development.

A new study links cranberries to better memory and lower stress hormones in students. But with industry funding, what's the real story behind the science?

The value retailer's 2026 food drive reveals a sophisticated new model, blending national scale with local impact to redefine corporate philanthropy.

A new partnership reveals the hidden engine of the AI boom: data center cooling. Discover how this tech levels the playing field and tackles AI's eco-impact.

Chinese mobility giant CaoCao and U.S. tech firm May Mobility are joining forces to commercialize robotaxis in Europe, a bold move in a high-stakes race.

Facing delisting, Virax Biolabs consolidates its shares in a bid to survive. This move buys time, but the real test lies in its innovative T-cell technology.